Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder

被引:204
作者
Horslen, SP [1 ]
McCowan, TC
Goertzen, TC
Warkentin, PI
Cai, HB
Strom, SC
Fox, IJ
机构
[1] Univ Nebraska, Med Ctr, Sect Pediat Gastroenterol, Omaha, NE 68198 USA
[2] Univ Nebraska, Med Ctr, Sect Surg, Omaha, NE USA
[3] Univ Nebraska, Med Ctr, Sect Radiol, Omaha, NE USA
[4] Univ Nebraska, Med Ctr, Sect Pathol, Omaha, NE USA
[5] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA
关键词
hepatocyte transplantation; infant; ornthine transcarbamylase deficiency; urea cycle disorder;
D O I
10.1542/peds.111.6.1262
中图分类号
R72 [儿科学];
学科分类号
100202 [儿科学];
摘要
Objective. Transplantation of isolated hepatocytes in animal models has been shown to correct inborn errors of metabolism. Based on these studies and our experience with hepatocyte transplantation in a child with Crigler-Najjar syndrome, isolated hepatocyte transplantation was performed to attempt metabolic reconstitution in a male infant with severe ornithine transcarbamylase (OTC) deficiency. Methods. An infant with an antenatal diagnosis of OTC deficiency was managed intensively to prevent hyperammonemia. Isolated hepatocytes were obtained by collagenase perfusion of donated livers not used for transplantation. Hepatocytes were infused in batches over the first 4 weeks of life via an umbilical venous catheter positioned in the portal vein. Immunosuppression consisted of tacrolimus and corticosteroids. Results. Over 4 billion viable hepatocytes were transplanted during the first 3.5 weeks of life. A period of metabolic stability was achieved between days 20 and 31 during which normal protein intake was tolerated while phenylbutyrate was weaned. During this time, plasma ammonia and glutamine remained within normal limits. Hyperammonemia reappeared abruptly on day 31 of life. Protein tolerance diminished to baseline; metabolic stability was subsequently reattained only following successful liver transplantation at 6 months of age. Conclusions. Isolated hepatocyte transplantation appeared to result in temporary relief of hyperammonemia and protein intolerance attributable to OTC deficiency. The metabolic stability achieved was lost after 11 days presumably because of rejection of the transplanted cells because of insufficient immunosuppression. Future attempts at isolated hepatocyte transplantation for inborn errors of metabolism in humans should include adequate immunosuppression and a liver biopsy as a means of proving hepatocyte engraftment and function.
引用
收藏
页码:1262 / 1267
页数:6
相关论文
共 16 条
[1]
BRENT L, 1981, TRANSPLANT P, V13, P860
[2]
BRUSILOW SW, 1995, METABOLIC BASIS INHE, V1, P1187
[3]
In vivo immunogenicity of purified allogeneic hepatocytes in a murine hepatocyte transplant model [J].
Bumgardner, GL ;
Li, JS ;
Heininger, M ;
Ferguson, RM ;
Orosz, CG .
TRANSPLANTATION, 1998, 65 (01) :47-52
[4]
Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation [J].
Fox, IJ ;
Chowdhury, JR ;
Kaufman, SS ;
Goertzen, TC ;
Chowdhury, NR ;
Warkentin, PI ;
Dorko, K ;
Sauter, BV ;
Strom, SC .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) :1422-1426
[5]
ORTHOTOPIC LIVER-TRANSPLANTATION FOR ORNITHINE TRANSCARBAMYLASE DEFICIENCY WITH HYPERAMMONEMIC ENCEPHALOPATHY [J].
HASEGAWA, T ;
TZAKIS, AG ;
TODO, S ;
REYES, J ;
NOUR, B ;
FINEGOLD, DN ;
STARZL, TE .
JOURNAL OF PEDIATRIC SURGERY, 1995, 30 (06) :863-865
[6]
Auxiliary liver transplantation for urea-cycle enzyme deficiencies: Lessons from three cases [J].
Kiuchi, T ;
Edamoto, Y ;
Kaibori, M ;
Uryuhara, K ;
Kasahara, M ;
Uemoto, S ;
Egawa, H ;
Inomata, Y ;
Tanaka, K .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) :528-529
[7]
HEPATOCELLULAR TRANSPLANTATION FOR METABOLIC DEFICIENCIES - DECREASE OF PLASMA BILIRUBIN IN GUNN RATS [J].
MATAS, AJ ;
SUTHERLAND, DER ;
STEFFES, MW ;
MAUER, SM ;
LOWE, A ;
SIMMONS, RL ;
NAJARIAN, JS .
SCIENCE, 1976, 192 (4242) :892-894
[8]
ORTHOTOPIC LIVER-TRANSPLANTATION IN LIVER-BASED METABOLIC DISORDERS [J].
MOWAT, AP .
EUROPEAN JOURNAL OF PEDIATRICS, 1992, 151 :S32-S38
[9]
Hepatocyte transplantation as a treatment for glycogen storage disease type 1a [J].
Muraca, M ;
Gerunda, G ;
Neri, D ;
Vilei, MT ;
Granato, A ;
Feltracco, P ;
Meroni, M ;
Giron, G ;
Burlina, AB .
LANCET, 2002, 359 (9303) :317-318
[10]
Neurological outcome of patients with ornithine carbamoyltransferase deficiency [J].
Nicolaides, P ;
Liebsch, D ;
Dale, N ;
Leonard, J ;
Surtees, R .
ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 86 (01) :54-56